Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy.

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, USA.
AIDS (London, England) (Impact Factor: 6.56). 05/2010; 24(11):1765-70. DOI: 10.1097/QAD.0b013e32833a0961
Source: PubMed

ABSTRACT To investigate the survival outcomes for non-Hodgkin lymphoma (NHL) in HIV-infected vs. uninfected patients from the same integrated healthcare system, and to identify prognostic factors for HIV-related NHL in the era of combined antiretroviral therapy.
A cohort study.
Incident NHL diagnosed between 1996 and 2005 were identified from members of Kaiser Permanente California Health Plans. Two-year all-cause and lymphoma-specific mortality by HIV status were examined using multivariable Poisson regression. Among HIV-infected patients, prognostic factors of demographics, lymphoma, and HIV-related characteristics for the same outcomes were also examined.
A total of 259 HIV-infected and 8230 HIV-uninfected incident NHL patients were evaluated. Fifty-nine percent of HIV-infected patients died within 2 years after NHL diagnosis as compared with 30% of HIV-uninfected patients. HIV status was independently associated with a doubling of 2-year all-cause mortality (relative risk = 2.0, 95% confidence interval 1.7-2.3). This elevated mortality risk for HIV-infected patients was similar for all race groups, lymphoma stages, and histologic subtypes. HIV-infected patients with CD4 cell count below 200 cells/microl, prior AIDS-defining illness, or both were also at increased risk for lymphoma-specific mortality as compared with HIV-uninfected patients. Among HIV-infected NHL patients, significant prognostic factors for overall mortality included prior AIDS-defining illness and Burkitt's subtype.
HIV-infected patients with NHL in the combined antiretroviral therapy era continue to endure substantially higher mortality compared with HIV-uninfected patients with NHL. Better management and therapeutic approaches to extend survival time for HIV-related NHL are needed.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: People living with HIV/AIDS (PLWHA) are at a higher risk of developing Non-Hodgkin Lymphoma (NHL). The influence of combined antiretrovirals (cART) on the presentation, treatment, and outcomes of HIV-associated NHL (HIV-NHL) warrants further investigation. We performed a retrospective analysis of PLWHA diagnosed with NHL, who received care at the Infectious Diseases Ponce de Leon Center in Atlanta, Georgia, from 1/1/2004 to 12/31/2010. Thirty-five patients with HIV-NHL were identified. Among these patients, 7 had Burkitt lymphoma (BL), 20 had diffuse large B cell lymphoma (DLBCL), 7 had plasmablastic lymphoma (PL), and 1 had primary effusion lymphoma (PEL). The majority of patients (82.9%) presented with advanced disease, and 63% were not on ART at diagnosis. Despite having good performance status at presentation, the majority of patients presented with high International Prognostic Index (IPI) scores. There were differences between the histologic subtypes of NHL in regards to treatment, complications, and outcomes. The median CD4 lymphocyte count at diagnosis was 110 cells/mm3 for patients with DLBCL (interquartile range (IQR): 66, 203), 165 cells/mm3 for Burkitt lymphoma (IQR: 36, 199), and 98 cells/mm3 for plasmablastic lymphoma (IQR: 34, 214). Overall, patients completed 67% of planned chemotherapy cycles. Common causes for chemotherapy termination were persistent myelosuppression (18.2%), social factors (22.7%), and disease progression (36.4%). Social factors included lack of transportation, substance abuse, unstable housing, and poor adherence. Two-year overall survival was 40% for all HIV-NHL. Half of patients with DLBCL (n=10), 42% of patients with PL (n=3), and only 14.3% of patients with BL (n=1) were alive at 2 years. Among the overall survivors at 2 years, 85.7% had CD4 > 200 cells/mm3 and 78.6% had undetectable HIV viral loads (VL) at that time.
    AIDS research and human retroviruses 04/2014; · 2.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer survival in persons with AIDS (PWA) after introduction of antiretroviral therapies remains poorly characterized. The aim is to provide population-based estimates of cancer survival, overall and for the most important cancer types in PWA, and a comparison with persons without AIDS (non-PWA) affected by the same cancers. PWA with cancer at AIDS or thereafter were individually matched with non-PWA by type of cancer, sex, age, year of diagnosis, area of living and, for lymphomas, histological subtype. Five-year observed survival and hazard ratios (HRs) of death in PWA versus non-PWA with 95% confidence intervals (CI) were estimated. We included 2262 Italian PWA and 4602 non-PWA with cancer diagnosed during 1986-2005. Between 1986-1995 and 1996-2005, 5-year survival for all cancers in PWA improved from 12% to 41% and the corresponding HR versus non-PWA decreased from 5.1 (95% CI: 4.3-6.1) to 2.9 (95% CI: 2.6-3.3). In 1996-2005, HRs were 2.0 (95% CI: 1.4-2.9) for Kaposi sarcoma; 3.4 (2.9-4.1) for non-Hodgkin lymphoma; 2.4 (1.4-4.0) for cervical cancer. HRs were 2.5 (2.1-3.1) for all non-AIDS-defining cancers; 5.9 (3.1-11.2) for Hodgkin lymphoma; and 7.3 (2.8-19.2) for non-melanoma skin. A ≤3-fold survival difference was found for cancer of the stomach, liver, anus, lung, brain and the most aggressive lymphoma subtypes. The persisting, although narrowing, gap in cancer survival between PWA and non-PWA indicates the necessity of enhancing therapeutic approaches, so that PWA will be provided the same chances of survival observed in the general population, and improving cancer prevention and screening.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 05/2014; · 4.39 Impact Factor
  • Source
    Revista medica de Chile 02/2012; 140(2):243-250. · 0.37 Impact Factor

Full-text (2 Sources)

Available from
Dec 10, 2014